European Growth OM1 recently expanded into Europe to better serve pharma and healthcare organizations with AI-enhanced real-world evidence solutions, signaling a strong market entry point for European clients seeking regulatory-grade longitudinal data and outcomes analytics. Sales opportunities include partnerships with European pharma, CROs, and payers, along with offerings of local data capabilities and regulatory support for multi-country studies.

Product Suite Cross-Sell The launch of AI powered products Orion, Lyra, and Polaris under the PhenOM platform demonstrates a robust suite for personalized medicine and clinical research. This creates opportunities to upsell to existing customers and attract new sponsors for trial recruitment, patient stratification, and comprehensive real-world evidence across chronic diseases and safety signals.

Chronic Disease Assets OM1 has launched chronic disease datasets such as Chronic Rhinosinusitis and Asthma, underscoring strengths in respiratory and inflammatory conditions. These datasets can be licensed to pharma for trial design, post-market surveillance, and outcomes research, offering clear cross-sell paths to CROs and payer networks.

Credibility & Growth Industry recognition with Frost & Sullivan awards and leadership appointments, including a General Manager from a large real-world evidence unit, alongside active ISPOR presence, bolster credibility with potential customers and partners. This can shorten sales cycles and support larger, enterprise-level deals.

RWE AI Advantage OM1's core value proposition centers on regulatory-grade deep longitudinal real-world data complemented by AI-powered analytics to accelerate evidence generation and clinical insights. This positions OM1 to support outcomes-based contracts, payer value demonstrations, and post-market safety monitoring for drugs and devices.